Document Detail


Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles.
MedLine Citation:
PMID:  20881836     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
5-Fluorouracil (5-FU) in combination with its synergistic biomodulator folinic acid maintains a pivotal position in cancer chemotherapy. However, clinical limitations such as phlebitis and catheter blockages persist with the administration of these drugs in combination, and are associated with reduced efficacy and/or quality of life for patients. We have reported earlier on the novel, all-in-one, pH neutral, parenteral 5-FU and folinic acid formulations (termed Fluorodex) incorporating β-cyclodextrins. Fluorodex maintains potency while overcoming the accepted incompatibility of 5-FU and folinic acid. We carried out toxicological, pharmacokinetic and biodistribution, and efficacy evaluations of Fluorodex compared with 5-FU:folinic acid using several administration routes and schedules in two rodent models. These were compared with the dose-matched sequential administration of 5-FU:folinic acid. Fluorodex showed bioequivalence to 5-FU:folinic acid as assessed by the tissue distribution and pharmacokinetic studies of 5-FU, but was generally better tolerated as determined by weight loss, hematological, and other clinical parameters. Compared with 5-FU:folinic acid, Fluorodex was also associated with reduced phlebitis using a rabbit ear vein model. Furthermore, using human carcinoma tumor models in mice, Fluorodex resulted in equivalent or improved efficacy profiles compared with 5-FU:folinic acid. In conclusion, these novel, all-in-one formulations represent a superior injectable form of 5-FU that allows codelivery of folinic acid. This should translate into improved patient tolerability with potential for enhanced efficacy.
Authors:
Tamantha K Stutchbury; Kara L Vine; Julie M Locke; Jeremy S Chrisp; John B Bremner; Philip R Clingan; Marie Ranson
Related Documents :
7396486 - Mouse bioassay for fusarium metabolites: rejection or acceptance when dissolved in drin...
12393296 - Folic acid, ascorbic acid and sodium selenite restore the motility of dictyostelium dis...
16317716 - Effects of chemoattractant pteridines upon speed of d. discoideum vegetative amoebae.
15019156 - Folic acid reduces nuclear translocation of beta-catenin in rectal mucosal crypts of pa...
15712666 - Two new biologically active illudane sesquiterpenes from the mycelial cultures of panae...
11239486 - Physiological regulation of the transport activity in the uncoupling proteins ucp1 and ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anti-cancer drugs     Volume:  22     ISSN:  1473-5741     ISO Abbreviation:  Anticancer Drugs     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-11-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100823     Medline TA:  Anticancer Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  24-34     Citation Subset:  IM    
Affiliation:
School of Biological Sciences, Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW 2522, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Second high-dose chemotherapy intensification followed by hematopoietic stem cell transplantation ap...
Next Document:  Immunohistochemistry Expression of P53, Ki67, CD30, and CD117 and Presence of Clinical Metastasis at...